Latest news with #Temab-A
Yahoo
03-06-2025
- Business
- Yahoo
AbbVie (NYSE:ABBV) Showcases Promising Phase 1 ADC Results For Advanced Cancers
AbbVie recently unveiled promising data on its investigational therapies, including the novel c-Met-targeting ADC, Temab-A, and the SEZ6-directed ADC, ABBV-706, indicating progress in their clinical pipelines. Despite these announcements, AbbVie's stock price remained flat, aligned with overall market stability. The market awaited significant financial updates, such as Nvidia's anticipated earnings report, contributing to a general holding pattern in stock movements. While AbbVie's steady price echoes broader market trends, the therapeutic advancements underscore the company's ongoing commitment to developing innovative treatments. Every company has risks, and we've spotted 5 weaknesses for AbbVie you should know about. We've found 17 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. The recent announcements regarding AbbVie's investigational therapies, including Temab-A and ABBV-706, stand to reinforce the narrative focused on pipeline growth and market expansion. These advancements could catalyze future revenues, particularly within the obesity and oncology sectors. This aligns with AbbVie's aim to leverage clinical progress to enhance financial outcomes, though immediate impacts on revenue and earnings forecasts might require more time to materialize. Given that the share price remained flat despite the positive pipeline developments, it appears the market is waiting for further validation of potential revenue contributions. Over the past five years, AbbVie's total shareholder return, combining share price appreciation and dividends, reached 150.37%, reflecting a robust long-term performance. In comparison, the company outperformed the US Biotechs industry, which saw a decline of 10.4% over the last year, highlighting AbbVie's relative strength in a challenging market environment. Currently, AbbVie's share price trades at approximately US$187.15, positioning it at a discount relative to the consensus price target of US$210.68. This indicates an 11.2% potential upside according to the analysts' expectations. The stability in the stock price, despite the recent news on clinical advancements, suggests investors might be holding out for more substantial financial data that aligns with the projected growth in revenues, where analysts foresee a progression to around US$70 billion by 2028. Unlock comprehensive insights into our analysis of AbbVie stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:ABBV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-06-2025
- Business
- Yahoo
ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons
AbbVie's antibody drug conjugate (ADC) Temab-A (telisotuzumab adizutecan) has demonstrated promising results in a Phase I trial in patients with lung cancer, as the ADC modality continues to take centre stage at this year's American Society of Clinical Oncology (ASCO) meeting. AbbVie's candidate, dubbed internally as ABBV-400, achieved an overall response rate (ORR) of 63% in patients with advanced EGFR (epidermal growth factor receptor)-mutated, non-squamous (NSQ) non-small cell lung cancer (NSCLC). The drug has already demonstrated positive data in patients with wildtype EGFR. Patients enrolled in the trial were those who had progressed after platinum-based chemotherapy doublet and tyrosine kinase inhibitor(s) (TKIs). Temab-A was administered every three weeks at one of two dose levels – 2.4 or 3 mg/kg. Immunotherapies currently on market are generally not recommended as first-line treatments for patients with EGFR mutation. Daiichi Sankyo and AstraZeneca's Enhertu (trastuzumab deruxtecan), the only ADC approved for NSCLC, previously demonstrated an objective response rate (ORR) of 49%. Enhurtu, however, is approved for HER2-mutant NSCLC, making direct comparisons difficult. AbbVie presented results from its Phase I trial (NCT05029882) at the 2025 ASCO Annual Meeting, taking place from 30 May to 3 June in Chicago, Illinois. The trial is enrolling around 500 adults with NSCLC, gastroesophageal adenocarcinoma, colorectal cancer (CRC) or advanced solid tumours. Data from the 41 patients enrolled demonstrated a median duration of response at 9.8 months and a median progression-free survival of 10.9 months. These figures were irrespective of c-Met expression, a protein found in NSCLC. Temab-A works by targeting c-Met and delivering a topoisomerase 1 inhibitor payload. Treatment emergent adverse events occurred in all patients, the most common being haematologic and gastrointestinal side effects. More serious events, those grade 3 and higher, occurred in 73% of patients. As with other ADCs, interstitial lung disease was observed – Temab-A generated a rate of 7% of this respiratory complication in participants. 'Data demonstrate a manageable safety profile, promising anti-tumour activity … and are supportive of further exploration of this novel ADC in this setting,' AbbVie's senior medical director of clinical development for solid tumours Nivedita Aanur told Pharmaceutical Technology. Nearly 85% of lung cancers are NSCLC, with initial treatment for patients with EGFR mutations including targeted therapy and/or chemotherapy. According to a GlobalData report, the global NSCLC market, valued at $30.7bn in 2021, is set to grow to $45.4bn by 2031. Approved immunotherapies in the market include MSD's Keytruda (pembrolizumab), Bristol Myers Squibb's Opdivo (nivolumab), and Roche's Tecentriq (atezolizumab). Daiichi Sankyo and AstraZeneca's ADC Enhertu won approval in NSCLC in the US and Europe in 2022 and 2023 respectively. Aanur comments: 'In addition to the data showcased at ASCO, it has now shown anti-tumour activity in both wild-type and EGFR-mutant advanced NSCLC, demonstrating its potential in these molecularly diverse populations. With its best-in-class potential, we believe Temab-A may offer meaningful patient impact compared to current standards of treatment.' Temab-A is also in Phase I/II (NCT06772623) development as a first-line treatment for NSCLC without actionable genomic alterations in combination with AbbVie's investigational programmed cell death 1 inhibitor budigalimab. AbbVie is also conducting separate Phase II (NCT06107413) and Phase III studies (NCT06614192) with the drug for CRC indications. AbbVie reported positive Phase II data last year for Teliso-V (telisotuzumab vedotin), also an ADC that targets the c-Met protein but uses a different payload, in EGFR-wildtype NSCLC patients. Other ADC data at ASCO this year include Genmab's rinatabart sesutecan for endometrial cancer treatment, MSD's zilovertamab vedotin for lymphoma, and Merck's precemtabart tocentecan for CRC. "ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
30-05-2025
- Business
- Yahoo
AbbVie Inc. (ABBV)'s Pipeline Advances with Temab-A and ABBV-706, Shares Flat
AbbVie Inc. (NYSE:ABBV) has spotlighted major advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, unveiling promising clinical data for its next-generation antibody-drug conjugates (ADCs), Temab-A and ABBV-706. Temab-A, a c-Met-targeting ADC, achieved a 63% objective response rate in pre-treated EGFR-mutated non-small cell lung cancer (NSCLC) patients, with over half maintaining their response for at least six months, demonstrating efficacy across c-Met expression levels and supporting further clinical exploration. A doctor utilizing a cloud-based healthcare platform to access patient records. ABBV-706, which targets SEZ6, delivered a 61% confirmed response rate in second-line or later small cell lung cancer (SCLC), outperforming existing therapies in cross-trial comparisons, while also showing activity in high-grade neuroendocrine neoplasms. Both therapies utilize AbbVie Inc. (NYSE:ABBV)'s proprietary Top1i payload to induce targeted cancer cell death, reinforcing the company's commitment to addressing difficult-to-treat tumors. Despite these clinical milestones, AbbVie Inc. (NYSE:ABBV)'s stock price remained steady at around $187.15, mirroring broader market stability as investors await key financial updates. With a consensus price target of $210.68, analysts see an 11% upside, highlighting ABBV's robust long-term performance and future revenue potential as its innovative pipeline matures. While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
29-05-2025
- Business
- Yahoo
AbbVie Inc. (ABBV)'s Pipeline Advances with Temab-A and ABBV-706, Shares Flat
AbbVie Inc. (NYSE:ABBV) has spotlighted major advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, unveiling promising clinical data for its next-generation antibody-drug conjugates (ADCs), Temab-A and ABBV-706. Temab-A, a c-Met-targeting ADC, achieved a 63% objective response rate in pre-treated EGFR-mutated non-small cell lung cancer (NSCLC) patients, with over half maintaining their response for at least six months, demonstrating efficacy across c-Met expression levels and supporting further clinical exploration. A doctor utilizing a cloud-based healthcare platform to access patient records. ABBV-706, which targets SEZ6, delivered a 61% confirmed response rate in second-line or later small cell lung cancer (SCLC), outperforming existing therapies in cross-trial comparisons, while also showing activity in high-grade neuroendocrine neoplasms. Both therapies utilize AbbVie Inc. (NYSE:ABBV)'s proprietary Top1i payload to induce targeted cancer cell death, reinforcing the company's commitment to addressing difficult-to-treat tumors. Despite these clinical milestones, AbbVie Inc. (NYSE:ABBV)'s stock price remained steady at around $187.15, mirroring broader market stability as investors await key financial updates. With a consensus price target of $210.68, analysts see an 11% upside, highlighting ABBV's robust long-term performance and future revenue potential as its innovative pipeline matures. While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
